Todd Sherer (MJFF) gave an update on c-Abl related matters a couple of days ago. He writes about the upcoming MJFF el al. trial, and also about the work of Inhibikase, and the work of Georgetown University:

Uncovering the Promise of c-Abl as a Therapeutic Target: Testing Available Treatments and Supporting New Therapies | Parkinson's Disease

Something else which may be of interest is the MJFF grant record for the current phase (i.e. the planning phase) of the MJFF et al. nilotinib trial:

Planning Phase for a Phase IIa Study of Nilotinib in People with Parkinson's Disease | Parkinson's Disease

and here is the MJFF grant record for the Inhibikase project:

Small Molecule Inhibitors of C-Abl for Parkinson's Disease Modification | Parkinson's Disease